Positron Emission Tomography (PET) Imaging of Brain Amyloid Compared to Post-Mortem Levels

• Status: Completed
• Trial end date: 2011-11-01
• Target enrollment: 0
• Participant gender: All

Summary

To determine the level of association between quantitative regional estimates of brain uptake of [18F]flutemetamol and quantitative immunohistochemical regional estimates of brain levels of amyloid estimated from post-mortem analysis of corresponding brain tissue samples.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GE Healthcare
• Collaborators: Covance; i3 Statprobe
• Treatments: Flutemetamol

Criteria

Inclusion Criteria:

• The subject has a short life expectancy (approximately 1 year or less) as estimated by the Investigator.

• The subject is 70 years of age or older if cognitively normal, or 55 years of age or older if terminal because of dementia.

• The subject's general health is adequate to undergo the study procedures.

Exclusion Criteria:

• The subject has a contraindication for PET.

• The subject has a known or suspected hypersensitivity/allergy to [18F]flutemetamol or to any of the excipients.

• The subject is unable to tolerate or cooperate with study procedures.